

From: [Melody Peters](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Wes Mellor](#); [Charles Rath](#); [Julie Pitruzzello](#); [Annie Praino](#); [Kristin Rademacher](#)
Subject: Notice of New Drug Introduction Pursuant to 18 V.S.A § 4637(b)-Avenacy
Date: Tuesday, May 28, 2024 3:13:42 PM
Attachments: [image001.jpg](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)

Some people who received this message don't often get email from melody.peters@rldatixlifesciences.com. [Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To the Office of the Attorney General:

Pursuant to 18 V.S.A § 4637(b), Avenacy provides notice that it intends to introduce to market the following on 5/27/2024 at a wholesale acquisition cost that exceeds the Medicare Part D Specialty Drug threshold:

NDC	Product Name	Product Description
83634-0303-01	ISOPROTERENOL HCL INJ 0.2MG/ML 10PK	ISOPROTERENOL HCL INJ 0.2MG/ML 10PK
83634-0303-05	ISOPROTERENOL HCL INJ 1MG/5ML 10PK	ISOPROTERENOL HCL INJ 1MG/5ML 10PK

Please reach out if you have any questions.

Regards,

Avenacy

10 N. Martingale Road Suite 225
Schaumburg, IL 60173
815-761-4125
Wes Mellor
wmellor@avenacy.com

Melody Peters | *Senior Commercial Analyst, Price Transparency*

T: + (856) 252-1510 | E: Melody.Peters@rldatixlifesciences.com

